Volume 9, Number 9—September 2003
Research
Ehrlichia chaffeensis Infections among HIV-infected Patients in Human Monocytic Ehrlichiosis–Endemic Area
Thomas R. Talbot*
, James A. Comer†, and Karen C. Bloch*
, James A. Comer†, and Karen C. Bloch*Table
Baseline characteristics of study cohort of HIV-positive persons residing in Tennesseea
| Characteristic | N (% or range) |
|---|---|
| Age (mean, y) |
38.8 (21–75) |
| Sex |
|
| Male |
107 (80.5%) |
| Female |
26 (19.5%) |
| Baseline CD4 count (median, cells/mm3) |
370 (6–1,200) |
| Baseline viral load (median, copies/dL) |
1,003 (<400–>750,000) |
| On prophylaxis |
|
| HAART |
122 (91.7%) |
| OI prophylaxis |
70 (52.6%) |
| PCP prophylaxisb |
66 (49.6%) |
| MAC prophylaxisc |
31 (23.3%) |
| Average number of clinic visitsd |
4.75 (1–13) |
| Treated with antibiotic therapyd,e |
40/133 (30.1%) |
| Treated with doxycyclined |
14/133 (10.5%) |
| Hospitalizedd | 7/133 (5.3%) |
aHAART, highly active antiretroviral therapy; OI, opportunistic infection; PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium avium complex.
bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine therapy.
cMAC prophylaxis: use of azithromycin or clarithromycin therapy.
dDuring the study period.
eAntibiotics used to treat the ongoing clinical symptoms; persons taking antibiotic therapy specifically for OI prophylaxis alone were not included.
